Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial

Ronald Kiguba, Norah Mwebaza, Ronald Ssenyonga, Helen Byomire Ndagiie, Victoria Nambasa, Cordelia Katureebe, Kenneth Katumba, Phil Tregunno, Kendal Harrison, Charles Karamagi, Kathryn A Scott, Munir Pirmohamed

ABSTRACT

Introduction Combination antiretroviral therapy (cART) has massively reduced HIV mortality. However, long-term cART increases the risk of adverse drug reactions (ADRs), which can lead to higher morbidity, mortality and healthcare costs for people living with HIV (PLHIV). Pharmacovigilance—monitoring the effects of medicines—is essential for understanding real-world drug safety. In Uganda, pharmacovigilance systems have only recently been developed, and rates of ADR reporting for cART are very low. Thus, the safety profile of medicines currently used to treat HIV and tuberculosis in our population is poorly understood.

The Med Safety mobile application has been developed through the European Union’s Innovative Medicines Initiative WEB-Recognising Adverse Drug Reactions project to promote digital pharmacovigilance. This mobile application has been approved for ADR-reporting by Uganda’s National Drug Authority. However, the barriers and facilitators to Med Safety uptake, and its effectiveness in improving pharmacovigilance, are as yet unknown.

Methods and analysis A pragmatic cluster-randomised controlled trial will be implemented over 30 months at 191 intervention and 191 comparison cART sites to evaluate Med Safety. Using a randomisation sequence generated by the sealed envelope software, we shall randomly assign the 382 prescreened cART sites to the intervention and comparison arms. Each cART site is a cluster that consists of healthcare professionals and PLHIV receiving dolutegravir-based cART and/or isoniazid preventive therapy. Healthcare professionals enrolled in the intervention arm will be trained in the use of mobile-based, paper-based and web-based reporting, while those in the comparison arm will be trained in paper-based and web-based reporting only.

Ethics and dissemination Ethical approval was given by the School of Biomedical Sciences Research and Ethics Committee at Makerere University (SBS-REC-720), and administrative clearance was obtained from Uganda National Council for Science and Technology (HS1366ES).

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This study will be delivered by researchers, policymakers, software developers, healthcare providers and consumers to promote medication safety in resource-limited settings.
⇒ We aim to recruit 3820 healthcare professionals from 382 combination antiretroviral therapy sites spread across Uganda; the selected study sites serve 80% of people living with HIV receiving combination antiretroviral therapy.
⇒ A limitation is that the use of the Med Safety mobile app requires a smartphone, but only 16% of Ugandans own a smartphone; limited rollout showed that 7 in 10 healthcare professionals are smartphone owners.

INTRODUCTION

Spontaneous adverse drug reaction (ADR) reporting is the backbone of pharmacovigilance (PV) globally but is plagued by under-reporting. Only 3% of Ugandan healthcare professionals (HCPs) reported a suspected ADR to the National Pharmacovigilance Centre (NPC) in 2014. These HCPs cited lack of conventional paper-based ADR forms (paper forms), limited access to web-based forms (web forms) due to the scarcity of internet-wired computers and the lack of feedback to ADR reporters as common barriers to PV. Also, logistical challenges lurk in the
countrywide distribution and collection of paper forms by Uganda’s NPC, which hinders timely data collation and analysis. Ultimately, the implementation of requisite policy actions to safeguard the public from medication-related harm has been delayed.

Innovative interventions are needed to improve ADR reporting, such as the use of mobile applications (mobile apps or apps) to support traditional PV. Mobile apps have had variable success in PV worldwide. A 10-fold increase in the rate of ADR reporting was seen for a medical device with social media engagement in the USA. In contrast, uptake of mobile app reporting has been poor in Europe: studies in the UK, the Netherlands and Croatia showed 1.7, 1.1 and 6.5 app ADR reports per completed month per 1000 app downloads, respectively. Uptake was also poor in India: 4.0 app ADR reports per completed month per 1000 app downloads. Efforts to strengthen PV in Uganda are timely due to the recent rollout of dolutegravir (DTG) as the preferred drug for first-line and second-line combination antiretroviral therapy (cART). DTG is more effective and tolerable and has a higher genetic barrier to developing drug resistance than other antiretrovirals. Rollout began in October 2018 and, by August 2019, over 347 888 people were initiated on IPT by September 2019 after a 100-day scale-up campaign. IPT significantly reduces the incidence of active TB, curbing TB-related mortality among PLHIV.

Although DTG is generally well tolerated, it is associated with serious ADRs including hyperglycaemia, neuropsychiatric effects (1.7%) and hepatotoxicity (0.1%). DTG is also associated with more common, but less serious, ADRs such as headache, abnormal dreams and abdominal pain, but the impact of these has not been evaluated in real-world settings in developing countries. The rapid rollout of DTG and scale up of IPT will increase the number of PLHIV exposed to these therapies, potentially increasing the incidence of ADRs, including serious ADRs, associated with these medicines. Discontinuation of DTG and/or IPT is recommended if serious ADRs such as jaundice, blurred vision or hyperglycaemia occur. Four in 10 000 PLHIV who receive IPT die due to an IPT-related adverse event.

ADRs can reduce quality of life for PLHIV and increase morbidity, mortality and healthcare costs. In 2016, prior to DTG rollout, the NPC attempted to improve spontaneous ADR reporting via a web form. However, they received only 92 online reports versus 290 paper-based ADR reports linked to cART from October 2018 to September 2019. More recently, a PV task force composed of the NPC, the AIDS Control Program and Ministry of Health was set up. The task force established an active drug safety monitoring and management programme to complement the spontaneous ADR reporting system. The NPC received 109 DTG-linked ADR reports from October 2018 to September 2019 from ~348 000 PLHIV. Only 18 IPT-linked ADR reports were received from January 2019 to June 2019 from ~300 000 PLHIV: 2.6 DTG-linked ADR reports per month per 100 000 treated PLHIV and 1.0 IPT-linked ADR report per month per 100 000 treated PLHIV. These rates are barely 5% the known incidence of the ADRs in PLHIV elsewhere.

The Med Safety mobile application was developed by the European Union Innovative Medicines Initiative: WEB-Recognising Adverse Drug Reactions. The same technology that produced the Med Safety App was also adopted by European countries including UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July 2015, Netherlands’ Lareb in January 2016 and Croatia’s HALMED in May 2016. In 2017, the Med Safety App was introduced in Africa (Burkina Faso and Zambia) in partnership with WHO. MHRA adapted Med Safety for low-income and middle-income countries (LMICs) including Uganda with approval from Uganda’s National Drug Authority (NDA) (figure 1). Med Safety was launched in limited settings in Uganda in February 2020.

Med Safety’s platform facilitates easy adoption and low-cost maintenance in LMICs. It is available at no cost for mobile phones and tablets, for Android and iOS, in English. Within the app, ADR reports can be completed
offline and transmitted to NPC when internet connectivity is established. The ADR reporting form has a clear and simple format. App users can browse and view ADR data and may create a ‘watch-list’ of medicines of their own interest to receive personalised news and alerts. Med Safety provides for two-way exchange of medication safety information between NPC and HCPs. This enhanced interaction promotes the involvement of HCPs in PV activities. The anticipated increase in volume of ADR reports in the national PV database could enhance its signal detection potential and contribute to remedial efforts to improve patient safety. The app is also integrated into the WHO Collaborating Centre for International Drug Monitoring – Uppsala Monitoring Centre application programme interfaces (including Vigiflow, VigiAccess and WHODrug). This study seeks to understand whether Med Safety is effective in improving ADR reporting by HCPs if used together with traditional PV methods versus if traditional PV methods are used alone.

Aims and objectives
Our aim is to assess the feasibility, effectiveness, cost and cost-effectiveness of implementing Med Safety for HCP-driven reporting of ADRs associated with DTG containing cART and IPT for TB prevention in PLHIV in Uganda. Our hypothesis is that the use of Med Safety for ADR reporting by HCPs attending to PLHIV on DTG-based cART and/or IPT will increase the ADR reporting rate by at least 25% versus use of existing PV methods alone in 30 months of follow-up at selected cART sites in Uganda. We will test our hypothesis in a pragmatic multicentre open-label cluster-randomised controlled trial whose specific objectives are to:

1. Assess the feasibility and acceptability of Med Safety for ADR reporting by HCPs at selected cART sites in Uganda.
2. Determine the app’s effect on the rate of ADR reporting versus traditional PV methods alone.
3. Estimate the app’s cost and cost-effectiveness from the provider perspective.

METHODS AND ANALYSIS
Participants, interventions and outcomes
Study setting
The study will be conducted nationwide at 382 (of 1832 cART sites) high volume accredited cART sites in Uganda. The 382 cART sites serve 80% of the PLHIV on cART in Uganda. This protocol follows the Standard Protocol Items: Recommendations for Intervenational Trials 2013 statement (online supplemental file 1).

Eligibility criteria
All smartphone-owning HCPs at these sites are eligible including: physicians, medical officers, pharmacists, nurses and midwives, clinical officers, pharmacy technicians and community health workers (lay counsellors and expert clients). Limited rollout showed that 7 in 10 HCPs are smartphone owners. Written informed consent will be sought from eligible HCPs. We expect to enrol 10 HCPs per cART site on average.

Intervention arm
HCPs at intervention cART-sites will be introduced to the Med Safety mobile app whether they own a smartphone or not. Mobile app, paper form and web form awareness campaigns including initial face-to-face training, posters/brochures and monthly reminder WhatsApp and mobile phone short messages (SMS) for up to 6 months will be undertaken. Training will be conducted by pharmacists from NPC and Makerere University with expertise in PV. The training teams have harmonised the training schedule to ensure uniform training. Interested HCPs with personal smartphones will be invited and assisted to install the mobile app and trained to use it to report suspected ADRs, with emphasis on DTG-linked and IPT-linked ADRs. HCPs will also be trained and encouraged to use traditional PV methods (paper form and web form).

Comparison arm
HCPs at the comparison cART-sites will be trained and encouraged to use traditional methods of ADR reporting (paper form and web form). All aspects of the training will be identical to those in the intervention arm except that Med Safety will not be introduced to HCPs in the comparison arm. Reminder WhatsApp and SMS about the paper form and web form will be sent out monthly for up to 6 months.

Outcomes
Our primary outcome is number of HCP-reported ADRs per 100 000 person-months of treated PLHIV per study arm. Our secondary outcomes are number of app ADR reports per 1000 app downloads per month of follow-up; causality (by Naranjo Scale and Liverpool Causality Assessment Tool); seriousness as per the WHO definitions (threatens life, ie, leads to or prolongs hospitalisation, causes incapacitation or death); ADR outcome; cost per ADR report; cost per additional ADR report; and cost per additional avoidable serious ADR report.

Participant timeline
There are 15 regional referral hospitals each with a catchment of ~25 cART sites. Each team of three research assistants requires 4 weeks to enrol HCPs in one regional catchment. Follow-up at each cART site begins after its enrolment and lasts 30 months. The 30-month follow-up period is considered adequate to monitor durability of the real-life impact of the app on ADR reporting. Four additional months will be required to wrap-up the study, thus, 36 months overall (table 1).

Sample size
To estimate the number of cART sites required per arm for an effect size of 25%, we assume power of 80% at the 95% confidence level, mean of 1.0 IPT-linked ADR/month/100 000 treated PLHIV (0.00001) and SD of 1.179 IPT-linked ADRs/month/100 000 treated PLHIV.
Table 1  Schedule of enrolment, interventions and assessments

<table>
<thead>
<tr>
<th>Study period</th>
<th>Baseline</th>
<th>Follow-up schedule</th>
<th>Close-out</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(t₀)</td>
<td>t₀+3 months</td>
<td>t₀+6 months</td>
</tr>
<tr>
<td><strong>Enrolment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation to study arm</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobile app arm</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Comparison arm</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td><strong>Assessments</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantitative survey</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Mobile app data</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Economic cost data</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Interim data analysis</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Qualitative study</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Endline data analysis</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

(0.00001179) (SD was computed based on the monthly IPT-linked ADR reports submitted to NPC for 1 year from October 2018 to September 2019), cluster size of 10 HCPs and coefficient of variation of 0.25,26 which yields ~114 cART sites per trial arm or 228 in both study arms. A minimum of 189 cART sites per arm or 378 in both study arms (66% increment) will be required to cater for the following limitations: (1) the large proportion of HCPs who do not own smartphones of ~50%–60% as previously estimated21 22 – and is 26% (95% CI of 23% to 30%) from limited rollout of RCT; (2) refusal to participate by eligible HCPs of ~5% as previously estimated27 – and is 0% (95% CI of 0% to 2%) from limited rollout of RCT; (3) loss to follow-up due to the relatively long follow-up period of 30 months (~10%); and (4) contamination due to information sharing between study arms through social media (~30%).28 We shall enrol 382 cART sites (191 per study arm) to cater for other unforeseen limitations; thus, recruiting up to 3820 HCPs (1910 HCPs per trial arm). Limited rollout of the RCT suggests a cluster size of 7.2 (629/87) HCPs. We shall retain the average cluster size of 10 HCPs because the RCT has not yet enrolled from the central region of Uganda (with the country’s capital city) where cART sites tend to be much larger with more HCPs per site than the more rural eastern, western and northern regions.

**Assignment of interventions**

**Unit of randomisation**

This unit is a cluster, defined as a cART site located at each of the 382 prescreened health facilities and consisting of HCPs and DTG/IPT-treated PLHIV. The use of cART sites as clusters minimises cointervention, duplication of reporting and organisational challenges and provides valid PLHIV population denominators for analysis of the outcomes.

**Concealment of sequence generation**

Using the sealed envelope software, an independent Biostatistician from the Clinical Epidemiology Unit at Makerere University, who will not participate in the subsequent data analyses, generated the block randomisation sequence to ensure balanced allocation of clusters.

**Randomisation**

The prescreened cART sites will be assigned by research assistants to the intervention and comparison arms, figure 2, using an electronically generated block randomisation sequence.

**Blinding**

PLHIV, HCPs, PV assessors of the ADR reports submitted to NPC and the biostatistician who will analyse the data will be blinded to the allocation of cART sites. The research assistants will not be blinded to the allocation of cART sites due to the nature of the intervention.
Data collection
Baseline survey
Consented HCPs will complete an interviewer-administered electronic questionnaire using the Open Data Kit software to record participants’ characteristics and details on ADR reporting. Details of the questionnaires are provided in (online supplemental file 2).

Mobile app data
The app is hosted by NDA where the NPC is located, which is also the preferred source of ADR risk information for users of the mobile app. HCPs with smartphones will submit reports that capture details on patient sociodemographics, suspected medicine, other concurrent medicines, suspected ADR and medical history. The NPC transmits alerts via the mobile app on emerging medication safety issues to users of the app.

Paper form and web form
The paper form and web form details will be distributed at all enrolled cART-sites. PV focal persons based at the cART-sites and NDA regulatory officers will routinely collect the paper forms and forward them to NPC for data capture in the national PV database and central analysis, prior to onward submission to the WHO database, VigiBase. HCPs also have the option to submit online ADR reports using the web form.

Economic cost data
Cost data will be collected by an appropriately trained RA. We will collect setup costs such as app development costs, equipment costs, cost of vehicles and training costs, and running costs such as airtime, internet data, app maintenance, personnel costs, buildings and space if any, transport (fuel), stationary, brochures, costs of registers and airtime/reminders. Both setup and 1-year running costs will be collected from the provider perspective.

Feasibility and acceptability of the app
Prior to trial implementation, we will conduct a baseline qualitative study to gauge the acceptability and feasibility of introducing the app to HCPs. We will conduct three to five focus group discussions each with five to eight HCPs and 20–30 in-depth interviews in a random 6% of cART-sites (~12) in the intervention arm. During trial implementation, we will document the refusal and failure rates to install the app among consented HCPs in the intervention arm. App users will be asked to report their experiences to gauge app feasibility, assess user satisfaction and identify potential revisions to the app. We will gauge acceptability of the app based on whether users can recommend the app to other HCPs to report suspected ADRs to NPC.

Data management
Training of research assistants
Both the initial and ongoing trainings focus on the key concepts of PV, good clinical practice, human subject protection, randomisation, risk profiles of cART and IPT and techniques for collecting high-quality survey data among others.

Data quality assurance
The PV database quality manager at NDA will be trained and empowered by the research team to embed data quality management in the national PV database.

Data protection
All ADR data are processed and securely stored by NPC. Paper forms are manually entered into the PV database by authorised NPC staff, while online data are electronically transmitted into VigiFlow and assessed before transfer into VigiBase. Researchers can request anonymised safety data for research purposes only. Paper-based questionnaires are stored under lock and key and accessed only by authorised project staff. Electronic data are password protected and used for research purposes only. Data will be delinked from HCP identifiers prior to analysis.

Compliance with allocation
Prior to data anonymisation, an NPC officer not involved in the routine assessment of submitted ADR reports will code these reports according to the allocated trial arm of the site where the report originates. Our team will use the codes to assess the extent of cross-over.

Data analysis
Success of randomisation
Baseline characteristics (sociodemographics of HCPs, pattern of smartphone ownership by HCPs at cART sites, geographical location of cART-site, nature and level of health facility, number and cadres of HCPs, number of PLHIV and use of DTG and IPT) will be compared in both study arms to establish if randomisation was successful.

Quantitative data
Analysis of results will be reported according to Consolidated Standards of Reporting Trials guidelines and performed on both intention-to-treat and per protocol bases. All ADR data received from the ~382 cART sites during the study period will be downloaded from VigiBase and anonymised by the PV manager at NPC and subsequently provided to the research team. Duplicate ADR reports will be identified and excluded from formal statistical analyses. The randomisation code will be broken after data analysis.

Unit of analysis
This unit will be an ADR site in keeping with the cluster-randomised design.

Analysis of missing or lost clusters
We will compare baseline characteristics of individuals in the lost clusters with the characteristics of individuals in the clusters that will have completed follow-up. If we find no significant differences between the clusters, we will conclude that our results do not include any differential

misclassification. If there are differences, however, we will report this finding and discuss its implications.

Descriptive statistics
We shall determine the frequencies of deduplicated HCP-reported ADRs per 100,000 treated PLHIV per cART site together with the time from ADR onset to VigiBase registration.

Effectiveness
Descriptive data will be aggregated to obtain the number of HCP-reported ADRs per 100,000 treated PLHIV per trial arm and compared at cluster level using the Student’s t-test or Wilcoxon rank-sum test, as appropriate, to determine if the app significantly increases ADR reporting. We will assess if the introduction of Med Safety increases the rate of ADR reporting by HCPs to NPC versus the use of existing PV methods (paper and online) alone during 30 months of follow-up and effect size of 25% at 5% level of statistical significance and power of 80%.

Multivariable analysis
Models will use the number of ADR reports as the outcome. Hierarchical models (level 1: cART sites; level 2: HCPs nested within cART sites; level 3: individuals nested within HCPs) will be fitted using maximum log-likelihood, considering intraclass correlations, using mixed models and generalised estimating equations models to control for potential confounders and effect modifiers identified at baseline assessment if fair randomisation fails. Subgroup analyses will also be performed.

Feasibility and acceptability of the app
We will compute the refusal rates and detail the reasons for failed mobile app installation by consented HCPs in the intervention arm. Qualitative data on the acceptability and barriers/facilitators of using the mobile app by HCPs will be analysed using thematic analysis by employing NVivo V.10 software.

Cost and cost-effectiveness
We will estimate unit setup and running costs for both the introduction of Med Safety in addition to existing PV methods and the use of existing PV methods alone. Costs per ADR report submitted to NPC will be computed (overall; per study arm; per ADR attribute, eg, seriousness, avoidability, causality, etc). We will estimate cost-effectiveness of introducing Med Safety by calculating the incremental cost-effectiveness ratio, which is the cost per additional ADR report submitted to NPC.

Monitoring
Monitoring and evaluation mechanism
The research team will monitor the project’s performance based on the research activities and report progress to the Project Steering Committee, which will sit (online) every 6 months. During monitoring, the research team will continually collect and analyse information on the project’s ongoing research activities. The steering committee will provide independent external evaluation of the project based on the 6-monthly reports from the research team.

Stopping rules
A Data Safety Monitoring Board is in place. Midterm interim analysis will be conducted at p < 0.01 to assess if the app is substantially better than a priori estimates. The study will otherwise stop when all 382 cART sites have been enrolled and followed up for 30 months. A protocol for patient care is in place at each cART site to evaluate and manage PLHIV who develop suspected ADRs linked to cART and IPT.

Ethics and dissemination
We obtained ethical approval for the study from the School of Biomedical Sciences Research and Ethics Committee at Makerere University College of Health Sciences (SBS-REC-720), and subsequently undertook research registration with the Uganda National Council for Science and Technology (HS1366ES). Administrative clearance is being obtained from participating cART sites and written informed consent sought from participating HCPs (online supplemental file 3).

Dissemination strategies
During the study, limited communication tailored specifically for each study arm will be made by the study team to limit the effect of contamination.

Engaging healthcare providers
We shall employ video conferencing, webinars and face-to-face engagements to deliver continuing professional education sessions to HCPs on ADR risk assessments for PLHIV prior to the initiation of DTG regimens and IPT and the detection, management and reporting of ADRs for PLHIV already receiving DTG/IPT. Video conferencing is preferred to minimise the spread of COVID-19. If virtual meetings are not feasible, then face-to-face meetings will be held in full observance of the Ministry of Health’s guidelines for limiting the spread of COVID-19: social distancing, use of face masks and handwashing, especially for regional trainings of HCPs in remote areas where the internet might not be accessible and during the enrolment of study sites. The NPC in concert with Ministry of Health developed PV training materials for active drug safety monitoring and management of ADRs to DTG/IPT. We shall adapt and update these materials with the results of our study for academic training and also tailor them for healthcare service delivery trainings to be conducted nationwide in partnership with NPC and Ministry of Health.

Reaching healthcare providers, policymakers and drug regulators
This work underpins the wider rollout of Med Safety to improve PV across Uganda and beyond. This study is being implemented in direct partnership with cART sites, Uganda’s NDA, which is the PV coordinating body in Uganda, UK’s MHRA and WHO. Therefore, the study
results will be readily available for immediate use to inform policy and practice by these key stakeholders. The NDA and MHRA (the software developers) will identify the barriers to the app’s implementation and mitigate them as well as the facilitators and exploit them. Uganda’s experience could be exploited to scale up the app in other low-income and middle-income countries.

Reaching researchers
In addition to social media and webinars, as mentioned previously, we aim to reach researchers through traditional methods. We shall present our work at conferences including: Joint Annual Scientific Health Conference, Makerere University College of Health Sciences; International Society of Pharmacovigilance Annual Meeting; Conference on Retroviruses and Opportunistic Infections; International AIDS Society Conference, Royal Society of Tropical Medicine and Hygiene Annual Meeting, among others. We expect to produce at least six open access publications from this work by the end of this study. We shall target journals including: Lancet Global Health; Drug Safety; Pharmacoepidemiology and Drug Safety, Journal of the International AIDS Society; Journal of Antimicrobial Chemotherapy; and Journal of Acquired Immune Deficiency Syndromes, etc.

Project impact
Improving the reporting of suspected ADRs via digital PV is the first step towards boosting the volume of safety data available for robust signal detection analyses, improving understanding of the risk profiles of medicines and preventing future occurrence of avoidable ADRs. Improved PV translates into better recognition of serious ADRs and, ultimately, safer patient care. This work underpins future proposals to understand the risk factors for ADRs in PLHIV.

Protocol amendments
Protocol modifications that may impact on implementation of the study and affect patient safety including changes of study objectives, study design, study population, sample sizes, study procedures or significant administrative aspects will require a formal protocol amendment. Such amendment will be agreed on by the study investigators and approved by the School of Biomedical Sciences Research & Ethics Committee prior to implementation.

Patient and public involvement
Patients were not involved in designing this study and will not be directly involved in the conduct, reporting and dissemination of the research. However, HCPs were involved in refining the study tools and will participate in conducting, reporting and disseminating the research.

Author affiliations
1 Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda
2 Department of Epidemiology & Biostatistics, College of Health Sciences, Makerere University, Kampala, Uganda
3 National Pharmacovigilance Centre, National Drug Authority, Kampala, Uganda
4 AIDS Control Programme, Ministry of Health, Kampala, Uganda
5 MRC/UWRI and LSHTM Uganda Research Unit, Entebbe, Uganda
7 Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
8 MRC Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine, Institute of Systems, Molecular and Integrative Biology (ISMB), University of Liverpool, Liverpool, UK

Acknowledgements
UK’s Medicines and Healthcare products Regulatory Agency and Uganda’s National Drug Authority provided technical and logistical support during the planning and implementation of this project.

Contributors
RK, HBN, VB, CK and MP designed the study. RK drafted the manuscript. RK, NW, RS, HBN, VN, CK, KRR, PT, KH, CK and MP critically reviewed and revised the final version of the manuscript. All authors read and approved the final manuscript.

Funding
This project is supported by the Medical Research Council (MR/ V3510X/1) and Makerere University Research & Innovations Fund (N/A).

Disclaimer
The funders had no role in study design, data collection and analysis, decision to publish or preparation of manuscripts.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Ronald Kiguba http://orcid.org/0000-0002-2636-4115
Ronald Ssenyonga http://orcid.org/0000-0002-2409-3593

REFERENCES
TB drugs among TB/HIV co-
Amuha MG, Kutyabami P
Uganda: pr
HIV Med
neuropsychiatric adverse events leading to dolutegravir
Hof
dolutegravir.
Elzi L, Erb S, Furr
O'Halloran JA, Sahrmann J, Parra-
ciacc355. [Epub ahead of print: 06 May 2022].
2022. doi:10.1093/cid/mellitus in people with HIV.
Clin Infect Dis
strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV.
Lancet HIV
hyperglycaemia in patients with HIV.
Lamor
Cassenote AJF
Braz J Infect Dis
HIV/AIDS cohort study.
GlaxoSmithKline. Pr
J Acquir Immune Defic Syndr
prophylaxis among people living with HIV/AIDS: a review of the literature.
56:56–57.
BMJ
T
based combination therapy in Uganda.
BMJ
T
et
Trials
randomized controlled trial.


<table>
<thead>
<tr>
<th>Administrative information</th>
<th>Reporting Item</th>
<th>Page and Line Number</th>
<th>Reason if not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>#1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>Page 1, line 1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>#2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>Page 2, line 26</td>
</tr>
<tr>
<td>Trial registration: data set</td>
<td>#2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>Yes (In trial register PACTR202009822379650)</td>
</tr>
<tr>
<td>Protocol version</td>
<td>#3</td>
<td>Date and version identifier</td>
<td>N/A</td>
</tr>
<tr>
<td>Funding</td>
<td>#4</td>
<td>Sources and types of financial, material, and other support</td>
<td>Page 11, line 11</td>
</tr>
<tr>
<td>Roles and responsibilities: contributorship</td>
<td>#5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>Page 1, lines 6-29 and Page 11, lines 8-10</td>
</tr>
<tr>
<td>Roles and responsibilities: sponsor contact information</td>
<td>#5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>N/A</td>
</tr>
<tr>
<td>Roles and responsibilities: sponsor and funder</td>
<td>#5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for</td>
<td>Page 11, lines 13-14</td>
</tr>
<tr>
<td>Roles and responsibilities: committees</td>
<td>#5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>Page 9, lines 28-33</td>
</tr>
</tbody>
</table>

| Introduction | | | |

| Background and rationale | #6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | Page 4, line 2 to Page 5, line 13 |

| Background and rationale: choice of comparators | #6b | Explanation for choice of comparators | Page 5, lines 11-13 |

| Objectives | #7 | Specific objectives or hypotheses | Page 5, lines 16-26 |

| Trial design | #8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory) | Page 5, line 21-22 |

### Methods: Participants, interventions, and outcomes

<p>| Study setting | #9 | Description of study settings (eg, community clinic, academic hospital) and list of countries | Page 5, line 29-32 |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Identifier</th>
<th>Details</th>
<th>Page/Line</th>
<th>Supplemental Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility criteria</td>
<td>#10</td>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)</td>
<td>Page 5, line 34-38</td>
<td></td>
</tr>
<tr>
<td>Interventions: description</td>
<td>#11a</td>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered</td>
<td>Page 5, line 40-48</td>
<td></td>
</tr>
<tr>
<td>Interventions: modifications</td>
<td>#11b</td>
<td>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)</td>
<td>N/A</td>
<td>No discontinuations/modifications are planned. Both intention-to-treat and per protocol analyses will be conducted</td>
</tr>
<tr>
<td>Interventions: adherence</td>
<td>#11c</td>
<td>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)</td>
<td>Page 5, lines 43-44 and Page 8, lines 30-32</td>
<td></td>
</tr>
<tr>
<td>Interventions: concomitant care</td>
<td>#11d</td>
<td>Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>Page 9, line 47-48</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>#12</td>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of</td>
<td>Page 6, lines 3-8</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>#</td>
<td>Description</td>
<td>Page/Lines</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Participant timeline</td>
<td>#13</td>
<td>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)</td>
<td>Page 6, line 10-15</td>
<td></td>
</tr>
<tr>
<td>Sample size</td>
<td>#14</td>
<td>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations</td>
<td>Page 7, lines 1-18</td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>#15</td>
<td>Strategies for achieving adequate participant enrolment to reach target sample size</td>
<td>Page 7, lines 7-15</td>
<td></td>
</tr>
</tbody>
</table>

**Methods: Assignment of interventions (for controlled trials)**

<table>
<thead>
<tr>
<th>Category</th>
<th>#</th>
<th>Description</th>
<th>Page/Lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation: sequence generation</td>
<td>#16a</td>
<td>Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions</td>
<td>Page 7, line 26-29</td>
</tr>
<tr>
<td>Allocation concealment mechanism</td>
<td>#16b</td>
<td>Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes),</td>
<td>Page 7, line 28</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
| Allocation: implementation | #16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | Page 7, line 31-33 |
| Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | Page 7, line 35-37 |
| Blinding (masking): emergency unblinding | #17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial | N/A |

**Methods: Data collection, management, and analysis**

| Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | Page 7, line 40 to Page 8, line 13, supplementary file 2 |
| Data collection plan: retention | #18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who | N/A |

This is a pragmatic trial in which no other interruption to real-life practice will be made – apart from introducing the mobile application at baseline and
<table>
<thead>
<tr>
<th>Data management</th>
<th>#19</th>
<th>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol</th>
<th>Page 8, line 16-32</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statistics: outcomes</td>
<td>#20a</td>
<td>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol</td>
<td>Page 8, line 35 to Page 9, line 26</td>
</tr>
<tr>
<td>Statistics: additional analyses</td>
<td>#20b</td>
<td>Methods for any additional analyses (eg, subgroup and adjusted analyses)</td>
<td>Page 9, lines 13-14</td>
</tr>
<tr>
<td>Statistics: analysis population and missing data</td>
<td>#20c</td>
<td>Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</td>
<td>Page 8, lines 41, 48</td>
</tr>
</tbody>
</table>

### Methods: Monitoring

| Data monitoring: formal committee | #21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed | Page 9, line 34 |

sending monthly mobile phone short message reminders for 6-months.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Code</th>
<th>Description</th>
<th>Page, Line</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data monitoring: interim analysis</td>
<td>#21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>Page 9, line 35</td>
<td></td>
</tr>
<tr>
<td>Harms</td>
<td>#22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>N/A</td>
<td>Introduction of the Med Safety App in the intervention arm is thought to be of very minimal risk.</td>
</tr>
<tr>
<td>Auditing</td>
<td>#23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>Page 9, line 35</td>
<td></td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research ethics approval</td>
<td>#24</td>
<td>Plans for seeking research ethics committee / institutional review board (REC / IRB) approval</td>
<td>[Page 9, line 41-44]</td>
<td></td>
</tr>
<tr>
<td>Protocol amendments</td>
<td>#25</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)</td>
<td>Page 10, line 37-41</td>
<td></td>
</tr>
<tr>
<td>Consent or assent</td>
<td>#26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>Page 9, line 45</td>
<td></td>
</tr>
<tr>
<td>Consent or assent: ancillary studies</td>
<td>#26b</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>N/A</td>
<td>No biological samples will be collected.</td>
</tr>
<tr>
<td>Topic</td>
<td>#</td>
<td>Description</td>
<td>Page/Line</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Confidentiality</td>
<td>#27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>Page 7, line 23-28</td>
<td></td>
</tr>
<tr>
<td>Declaration of interests</td>
<td>#28</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>Page 11, line 15</td>
<td></td>
</tr>
<tr>
<td>Data access</td>
<td>#29</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>Page 11, line 18</td>
<td></td>
</tr>
<tr>
<td>Ancillary and post trial care</td>
<td>#30</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Dissemination policy: trial results</td>
<td>#31a</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
<td>Page 9 lines 47 to Page 10, line 29</td>
<td></td>
</tr>
<tr>
<td>Dissemination policy: authorship</td>
<td>#31b</td>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
<td>Page 11, line 8-10</td>
<td></td>
</tr>
<tr>
<td>Dissemination policy: reproducible research</td>
<td>#31c</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>Page 11, line 18-22</td>
<td></td>
</tr>
</tbody>
</table>
## Appendices

<table>
<thead>
<tr>
<th>Informed consent materials</th>
<th>#32</th>
<th>Model consent form and other related documentation given to participants and authorised surrogates</th>
<th>Supplementary file 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological specimens</td>
<td>#33</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Biological specimens will not be collected

It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.
Adverse drug reaction (ADR) is an unwanted or harmful reaction experienced following the administration of a drug or combination of drugs under normal doses/conditions of use & is suspected to be related to the drug. An ADR might require the drug to be discontinued or the dose reduced.

SECTION A: DEMOGRAPHICS

1. Gender:
   [1] Male
   [2] Female

2. Age (in completed years): _____

3. Do you own a working smartphone?
   [1] Yes
   [2] No

3a) If YES to Q3, are you willing to join a WhatsApp group?  [1] Yes  [2] No

3b) If YES to Q3a, can you share your WhatsApp number? _____________

4. Do you own a simple working mobile phone (not a smartphone)?
   [1] Yes
   [2] No

5. Highest Education Level:
   [1] Certificate
   [2] Diploma
   [3] Bachelors
   [5] Other, (specify) _____________

6. Professional experience (Years):

7. If less than 1 year in Q5, state number of completed months _____

8. Do you use any of the following? (Tick all that apply)
   [1] WhatsApp
   [2] Facebook
   [3] Twitter
   [4] Other, (specify) _____________

9. Professional Cadre:
   [1] Physician
   [2] Medical Officer
   [3] Pharmacist
   [4] Nurse/Midwife
   [5] Clinical Officer
   [6] Pharmacy Technician
   [7] Lay Counsellor
   [8] Expert Client
   [9] Other, (specify) _____________

10. Health Facility Type:
    [1] Public
    [2] Private Not-for-Profit
    [3] Private for-Profit

11. Health Facility Status:
    [1] Regional Referral Hospital
    [2] Hospital
    [3] Health Centre IV
    [5] Health Centre II
    [6] Private Clinic
    [7] Other, (specify) _____________
SECTION B: DOLUTEGRAVIR-LINKED AND ISONIAZID-LINKED ADRS

Please, complete the questionnaire by indicating the appropriate responses.

1. What is the approximate number of HIV-positive patients you see per day? ____

Dolutegravir-linked adverse drug reactions

2. Dolutegravir-based antiretroviral therapy was recently rolled out in the treatment of HIV-positive patients, have you ever encountered any dolutegravir-linked adverse drug reactions (ADRs) amongst the HIV-positive patients in your care?

3. In the past 4-weeks, have you suspected any dolutegravir-linked ADRs?
   [1] Yes   [2] No (Skip to 5)   [9] I don’t know (Skip to 5)

4. If YES to Q3, how many cases of dolutegravir-linked ADRs have you suspected in the past 4-weeks? ____

5. In the past 4-weeks, have you received any patient-complaints of dolutegravir-linked ADRs?
   [1] Yes   [2] No (Skip to 7)   [9] I don’t know (Skip to 7)

6. If YES to Q5, how many patient-complaints of dolutegravir-linked ADRs have you received in the past 4-weeks? ____

7. Briefly describe the most recent dolutegravir-linked ADR you have encountered giving details on patient age, sex, approximate ADR-date, details of the adverse drug reaction, severity (mild, moderate, severe), seriousness (led to or prolonged hospitalization, caused incapacitation, led to any other medically significant condition or death), clinical outcome & action taken:

   Patient age [   ] years; sex [ M or F]; approximate ADR-date [mm/yyyy: __ / ____ ]

   ADR description (include severity, seriousness, clinical outcome and action taken)

   ________________________________________________________________
   ________________________________________________________________
   ________________________________________________________________
   ________________________________________________________________

Isoniazid preventive therapy-linked adverse drug reactions

8. HIV-positive patients are at a higher risk of dying when they develop active tuberculosis (TB). During the past one year, Ministry of Health scaled up the roll-out of isoniazid preventive therapy (IPT) among HIV-positive patients to significantly reduce these patients’ risk of developing active TB. IPT, however, has been associated with ADRs. Have you ever encountered any IPT-linked ADRs amongst the HIV-positive patients in your care?

9. In the past 4-weeks, have you suspected any isoniazid preventive therapy-linked ADRs?
   [1] Yes   [2] No (Skip to 11)   [9] I don’t know (Skip to 11)
10. If YES to Q9, how many isoniazid preventive therapy-linked ADRs have you suspected in the past 4-weeks? _____

11. In the past 4-weeks, have you received any patient-complaints of isoniazid preventive therapy-linked ADRs?
   [1] Yes       [2] No (Skip to 13)       [9] I don’t know (Skip to 13)

12. If YES to Q11, how many patient-complaints of isoniazid preventive therapy-linked ADRs have you received in the past 4-weeks? _____

13. Briefly describe the most recent isoniazid-linked ADR you have encountered giving details on patient age, sex, approximate ADR-date, details of the adverse drug reaction, severity (mild, moderate, severe), seriousness (led to or prolonged hospitalization, caused incapacitation, led to any other medically significant condition or death), clinical outcome & action taken:

   Patient age [   ] years; sex [ M or F]; approximate ADR-date [mm/yyyy: __ / ____ ]

   ADR description (include severity, seriousness, clinical outcome and action taken)_______________________________________________________________
   ___________________________________________________________________
   ___________________________________________________________________
   ___________________________________________________________________
   ___________________________________________________________________
   ___________________________________________________________________

14. In the past 6-months, have you reported any suspected ADRs experienced by the HIV-positive patients under your care?
   [1] Yes       [2] No (Skip to Q23)       [9] I don’t know (Skip to Q23)

15. If YES to Q14, how many ADR reports did you make? [   ] [   ]

16. If YES to Q14, which drug classes were suspected? (Tick all that apply)
   [1] Antiretroviral therapy
   [2] Isoniazid preventive therapy
   [4] Other, (specify)__________________________________________________________

17. If YES to Q14, which of the following drugs were implicated? (Tick all that apply and mention number of reported ADRs in past 4-weeks for options [1] & [2])
   [1] Dolutegravir: Number of ADRs reported in the past 4-weeks _____
   [2] Isoniazid: Number of ADRs reported in the past 4-weeks _____
   [3] Other, (specify)______________
18. If YES to Q14, to whom did you report the most recent ADR? (Tick all that apply)
   [1] District Health Officer
   [3] Immediate Supervisor
   [5] Other, (specify)__________________

19. If YES to Q14, how did you report the most recent suspected ADR? (Tick all that apply)
   [1] Verbally
   [3] Written online/website report
   [4] Other, (specify)__________________

20. If YES to Q14, did you get feedback on the ADR(s) you reported?

21. If YES to Q20, what form of feedback?
    _________________________________________________________________
    _________________________________________________________________

22. In special situations, the National Drug Authority may need additional information
    about reported ADRs. Would you be willing to answer further questions after
    sending a report?

Herbal Medicine Use

23. In the past 6-months, have you suspected that some of your patients use herbal

24. If YES to Q23, have you inquired from the patients whether they use herbal

25. In the past six months, have any of your patients reported to you that they use

26. Have any of your patients presented with ADRs likely to be linked to the use of

We appreciate the time you’ve taken to respond to this survey. Thank you!
Health Facility Data

Research Assistant: ____________________     Code: 
Region: ______________________________      Code: 
Health Facility Name: ____________________________ Code: 
Date of Enrolment of Health Facility: ____/_____/_____

Average daily number of ART patient visits at the Health Facility: [ ] [ ] [ ]
Total number of patients on dolutegravir-containing antiretroviral therapy [ ] [ ] [ ] [ ]
Total Number of patients on Isoniazid Preventive Therapy [ ] [ ] [ ] [ ]

Number of healthcare professionals at the Health Facility:

- Medical Doctors [ ] [ ]
- Pharmacists [ ] [ ]
- Clinical Officers [ ] [ ]
- Nurses/Midwives [ ] [ ]
- Pharmacy Technicians [ ] [ ]
- Village Health Teams [ ] [ ]
- Lay Counsellors [ ] [ ]
- Expert Clients [ ] [ ]
- Other (specify) …………………………… [ ] [ ]

Does the Health Facility provide health workers with internet access?
1. No  2. Yes  9. Unknown

If YES, describe the form of internet access provided (wireless, wired, data etc.):
_____________________________________________________________________
_____________________________________________________________________

Is mobile telephone network connectivity available at the Health Facility?
1. No  2. Yes  9. Unknown

If YES, describe the reliability of mobile telephone network connectivity:
_____________________________________________________________________
_____________________________________________________________________

---

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Informed Consent Form

Purpose of the study: Experts from National Drug Authority and Makerere University College of Health Sciences are working together to improve the rate and quality of reporting of adverse drug reactions linked to the newly rolled-out dolutegravir-containing antiretroviral therapy and scaled up isoniazid preventive therapy to reduce the risk of tuberculosis in HIV-positive people. This project focuses on the involvement of healthcare professionals in the active drug safety monitoring and management of adverse drug reactions to these drugs and how this system can be improved.

Procedures: In this survey, we ask you to recall and describe the most recent suspected and/or reported adverse drug reactions (ADRs) linked to the use of dolutegravir-containing antiretroviral therapy and isoniazid preventive therapy among the HIV-positive people in your care; and any ADRs you have suspected in the past 4-weeks and/or ADR-complaints you have received from HIV patients in the past 4-weeks. The survey is anonymous and will take no more than 20-30 minutes to complete. After the interview, we shall provide you with the tools you will use to report any adverse drug reactions you encounter, particularly those linked to the use of dolutegravir and isoniazid preventive therapy. You will be contacted by phone at the end of the study to obtain feedback from you about your experience while using the tools for reporting adverse drug reactions. You could even be invited to participate in a group or individual in-depth discussion to share your experiences.

Time compensation: We greatly appreciate your time and opinion. The time you spend filling in this questionnaire will be compensated at a rate of UGX 20,000.

Confidentiality: Any information obtained in this study that can identify you will remain confidential and be disclosed only with your permission or as required by law. Otherwise, confidentiality will be maintained because the self-completed questionnaire is anonymous. We will not request for your name in the information we get from this study.

Participation and withdrawal: Participation is voluntary and you can withdraw at any time.

Identification of Investigators: If you have any questions or concerns about the research, please feel free to contact: Dr. Ronald Kiguba, Principal Investigator, Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Makerere University College of Health Sciences, Tel: +256712840683 & email: kiguba@yahoo.co.uk

Rights of participants: The School of Biomedical Sciences Research & Ethics Committee and the Uganda National Council for Science & Technology (UNCST) have reviewed my request to conduct this project. If you have any concerns about your rights in this study, please contact Dr. Erisa Mwaka Tel: +256 752575050 & email: erisamwaka@gmail.com OR UNCST on +256 414 705500 / +256 312 314800

I understand the procedures described above. My questions have been answered to my satisfaction, and I agree to participate in this study. I have been given a copy of this form.

Signature of participant: __________________________ Date: __________________________

Signature of research assistant: __________________________ Date: __________________________